How do you approach non-metastatic castration-resistant prostate cancer?
For which patients would you consider addition of apalutamide or enzalutamide? How do you decide between the 2 drugs?
Community PollStarted
Are you satisfied with long term safety of the novel AR targeted based on current information ?
20 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Johns Hopkins University
Answered on
The two recent placebo controlled trials comparing apalutamide and enzalutamide in M0CRPC (SPARTAN and PROSPER) have shown sizeable and consistent effects on various outcome measures, clearly met the primary study endpoints and hence satisfied FDA regulatory criteria for drug approval in this space....
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Stanford University Medical Center
Answered on
Would use older drugs like nilutamide. Better imaging studies in the future may allow us to detect metastases sooner. Drugs like enzalutamide and abiraterone not approved for this indication and maybe challenging to get insurance to approve
Join for free or sign in to see the full answer